Low energy, poor recovery, and a drive that is not showing up the same way are worth taking seriously, and they are worth understanding. Here is how we can help.
With Brian Moogan, FNP-BC, PMHNP-BC, APRN
Evaluation and treatment for low testosterone when it is clinically appropriate, with careful lab monitoring along the way. For the energy that runs out early, the drive that is not showing up the same way, and the recovery that takes longer than it used to.
Peptide therapy as part of an individualized plan, when it is appropriate for you. Ask about current options at your consultation.
Your thyroid, your nutrition, your sleep, your stress, and the nutrients your body depends on all shape how you feel. They are part of your care here, with labs when they are clinically appropriate.
Ongoing care with your provider, with regular follow up and adjustments as your needs change. Ask about membership options at your consultation.
Low testosterone is diagnosed with symptoms plus two early morning blood tests below 300 ng/dL. One low number alone is not enough.
The largest safety study to date, TRAVERSE, followed 5,246 men with heart disease or high heart risk for about three years. Heart attack, stroke and heart related death occurred in 7.0% of men on testosterone and 7.3% of men on placebo. In 2025 the FDA removed the heart risk language from the testosterone black box warning. The FDA also added a blood pressure warning, so we check your blood pressure at every step.
What improved: sexual activity and desire, and anemia. What did not change: erectile function and progression to diabetes. What surprised researchers: men on testosterone had more fractures, and the reason is still unknown.
Current research has not generally shown higher prostate cancer rates with testosterone. We still screen and monitor.
If you want children in the future, tell us first. Guidelines call for a fertility evaluation before starting.
Lifestyle is part of every plan. Choosing not to start testosterone is a valid choice too.
Sources: American Urological Association Testosterone Deficiency Guideline; TRAVERSE Trial, New England Journal of Medicine, 2023, and substudies; US Food and Drug Administration, 2025 testosterone labeling changes.
Book a consultation, and we will talk about what has changed and what you want back.
